Live Q&A: ADHD Can Be a Moving Target: Equip Yourself with the Tools to Detect and Manage ADHD to Reduce Its Burden
Premiere Date: Tuesday, August 2, 2022This activity will offer CE credit for:
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, August 2, 2023
Note: Credit Is No Longer Available
 | Ann Childress, MD (Moderator) President, Center for Psychiatry and Behavioral Medicine, Inc. Associate Professor Child/Adolescent Psychiatry Touro University Nevada College of Osteopathic Medicine Henderson, NV Clinical Associate Professor University of Nevada, Las Vegas School of Medicine Las Vegas, NV |
 | Timothy E. Wilens, MD Chief, Division of Child & Adolescent Psychiatry Co-Director, Center for Addiction Medicine Massachusetts General Hospital Professor of Psychiatry Harvard Medical School Boston, MA |
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that can persist into adulthood, with a course that impacts brain morphology, cognitive and psychosocial functioning, and psychiatric and medical comorbidities. Subsequently, ADHD is associated with an increased risk of morbidity and mortality. Diagnosis is complicated in that symptom presentation may vary as the individual transitions from childhood to adulthood. Several therapies, including stimulants and non-stimulants, are available for the management of ADHD; however, determining which therapy is best suited for the individual can be challenging. Educating patients, parents, and caregivers about available pharmacotherapies and the importance of treatment adherence will improve psychosocial functioning and quality of life. It is critical to provide awareness, timely diagnosis, and personalized treatment to both patients and parents of children with ADHD.
This live Q&A session is your opportunity to ask questions based on the CMEO Snack series that focused on recognizing the extensive burden and impact of ADHD, implementing appropriate tools to facilitate the early detection of ADHD in adults, providing optimal strategies to personalize care, and reviewing ADHD treatment options and therapeutic management.
At the end of this CE activity, participants should be able to:
- Identify the extensive burden imposed by ADHD, including brain morphology, cognitive and psychosocial functioning, and psychiatric and medical comorbidities.
- Utilize updated criteria and screening tools to accurately diagnose ADHD in adults.
- Develop personalized treatment strategies for children and adults with ADHD that consider safety, efficacy, and formulation as well as individual preferences and personal goals for therapy.
- Educate patients and caregivers about the available ADHD medication profiles, behavioral therapies, and significance of adherence to therapy.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Psychiatrists, psychiatric nurses, pediatricians, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists
Specific CE Credit information is not available at this time. Please check again soon!
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Childress reports the following financial relationships:
Consultant: Aardvark Therapeutics, Inc.; Corium Inc.; Jazz Pharmaceuticals, Inc.; KemPharm, Inc.; Lumos Pharma; Neos Therapeutics, Inc.; Noven Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Tulex Pharmaceuticals
Research Support: Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Allergan; Arbor Pharmaceuticals; KemPharm, Inc.; Neos Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc.
Speakers Bureau: Corium Inc.; Ironshore Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc.
Other Financial or Material Support: Writing support for Purdue Pharma L.P.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Wilens reports the following financial relationships
Consultant: Arbor Pharmaceuticals; Bay Cove Human Services, Inc.; Ironshore Pharmaceuticals Inc; Gavin Foundation; KemPharm, Inc.; Otsuka America Pharmaceutical, Inc; Vallon Pharmaceuticals; US Minor/Major League Baseball; US National Football League (ERM Associates); and White Rhino/3D
Grants and Research Support: NIH National Institute on Drug Abuse (NIDA)
Royalties/Intellectual Property: Cambridge University Press; Guildford Press; and Ironshore Pharmaceuticals Inc.
Other Financial or Material Support: Massachusetts General Hospital (Employee)
The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
SNQ-154-080222-20
